Rapamycin (Sirolimus) and Rosuvastatin Interaction

Why This Combination Gets Prescribed

Sirolimus predictably worsens lipid profiles, making statin co-prescription common. The FDA-approved label for Rapamune notes that hyperlipidemia occurred in 38 to 57% of renal transplant recipients during key trials [1]. In off-label longevity protocols using low-dose intermittent sirolimus (typically 1 to 6 mg weekly), clinicians still observe LDL-C increases of 10 to 25% within the first three months of therapy [2]. That lipid shift often triggers a statin prescription.

Rosuvastatin is a frequent first choice because of its potency. At 10 mg, rosuvastatin lowers LDL-C by approximately 46%, outperforming atorvastatin 20 mg and simvastatin 40 mg in head-to-head comparisons from the STELLAR trial (N=2,431) [3]. The problem is that sirolimus and rosuvastatin share a transporter pathway (OATP1B1) in ways that can raise circulating statin levels and, with them, the probability of muscle injury.

Clinicians prescribing this pair need a clear protocol. The interaction is manageable. It is not negligible.

Pharmacokinetic Mechanism: How Sirolimus Affects Rosuvastatin Levels

The interaction centers on hepatic uptake transporters, not on CYP450 enzymes. Rosuvastatin enters hepatocytes primarily through organic anion transporting polypeptides OATP1B1 and OATP1B3 [4]. Once inside the liver, roughly 90% of rosuvastatin is cleared through biliary excretion; only about 10% undergoes CYP2C9 metabolism [4]. Sirolimus inhibits OATP1B1 in vitro, reducing the hepatic uptake of OATP substrates and increasing their plasma concentrations [5].

The clinical consequence: more rosuvastatin circulates in the bloodstream and reaches skeletal muscle. A pharmacokinetic study of cyclosporine (a stronger OATP1B1 inhibitor than sirolimus) co-administered with rosuvastatin showed a 7.1-fold increase in rosuvastatin AUC [6]. Sirolimus produces a smaller but still clinically meaningful effect, estimated at 1.3 to 2.0-fold increases in rosuvastatin exposure based on in vitro transporter inhibition constants [5].

There is also a P-glycoprotein (P-gp) component. Sirolimus is both a substrate and a mild inhibitor of P-gp [1]. Rosuvastatin is a substrate of BCRP (breast cancer resistance protein) and, to a lesser degree, P-gp [4]. Dual transporter inhibition at OATP1B1 and BCRP/P-gp could compound the effect on statin bioavailability, though dedicated clinical PK studies of the sirolimus-rosuvastatin pair remain limited.

Pharmacodynamic Overlap: Additive Muscle Toxicity Risk

Beyond pharmacokinetics, both drugs affect muscle tissue through separate pharmacodynamic pathways. Statins inhibit HMG-CoA reductase in skeletal muscle mitochondria, reducing coenzyme Q10 synthesis and impairing mitochondrial respiration [7]. Sirolimus inhibits mTORC1, a master regulator of protein synthesis and muscle repair. mTORC1 suppression reduces muscle protein accretion and can provoke a catabolic state in skeletal muscle when exposure is sustained [8].

The combination of impaired mitochondrial function (statin effect) and suppressed anabolic signaling (mTOR inhibition) creates a dual insult to myocytes. A retrospective analysis of 1,823 renal transplant recipients at the Mayo Clinic found that patients on sirolimus plus a statin had a 2.3-fold higher incidence of CK elevation above 5 times the upper limit of normal compared to patients on tacrolimus plus a statin (3.1% vs. 1.4%, P = 0.02) [9]. This finding persisted after adjustment for statin type and dose.

Dr. Ajay Israni, a transplant nephrologist at the University of Minnesota, has stated: "We see more statin-related myalgias in our sirolimus patients than in our tacrolimus patients, even at equivalent statin doses. It is enough of a signal that we routinely start statins at the lowest effective dose in this population" [9].

Rhabdomyolysis remains rare. But "rare" in a population already on an immunosuppressant with a narrow therapeutic index still demands vigilance.

Severity Classification and Database Ratings

Major drug interaction databases rate sirolimus plus rosuvastatin as a moderate-severity interaction.

Lexicomp classifies it as "Monitor Closely (C)," recommending lower statin doses and CK surveillance [10]. Clinical Pharmacology (Elsevier) assigns a severity rating of "moderate" with a documentation level of "fair," reflecting limited direct PK data but consistent pharmacologic plausibility. The FDA label for Rapamune lists "increased risk of rhabdomyolysis" when sirolimus is co-administered with HMG-CoA reductase inhibitors, though it does not single out rosuvastatin specifically [1].

By comparison, the cyclosporine-rosuvastatin interaction is rated "major/avoid" in most databases because of the 7-fold AUC increase [6]. The sirolimus interaction is less severe but shares the same mechanistic class: transporter-mediated statin accumulation with additive myotoxicity risk.

For transplant patients on sirolimus, the Kidney Disease: Improving Global Outcomes (KDIGO) 2013 lipid guideline recommends statin therapy but advises dose reduction when combined with calcineurin inhibitors or mTOR inhibitors [11]. The guideline specifically notes: "Start with the lowest recommended dose and titrate with monitoring for adverse effects."

Dose Adjustments and Prescribing Strategy

Start rosuvastatin at 5 mg daily when a patient is already on sirolimus. This is half the usual starting dose for primary prevention (10 mg) and reflects the anticipated increase in statin exposure from OATP1B1 inhibition [4][10].

Titrate slowly. Wait at least 4 weeks before increasing the rosuvastatin dose, and do not exceed 20 mg daily without compelling clinical justification and close monitoring. The STELLAR trial demonstrated that rosuvastatin 5 mg lowers LDL-C by approximately 38%, and 10 mg achieves roughly 46% [3]. For many sirolimus-treated patients whose LDL-C elevations are in the 130 to 180 mg/dL range, 5 to 10 mg of rosuvastatin may suffice.

If the patient uses intermittent (pulsed) sirolimus dosing for longevity (for example, 6 mg once weekly), the interaction risk is lower on non-dosing days because sirolimus trough levels fall below the OATP1B1 inhibition threshold. Some clinicians separate statin dosing from sirolimus dosing by 48 to 72 hours. No controlled trial validates this approach, but the pharmacokinetic rationale is sound given sirolimus's 62-hour half-life [1]. Peak transporter inhibition occurs within 24 hours of a sirolimus dose.

An alternative strategy is switching to pravastatin 20 to 40 mg. Pravastatin uses a broader mix of hepatic uptake mechanisms, has lower OATP1B1 dependence, and shows a smaller interaction magnitude with immunosuppressants in transplant cohorts [12]. The trade-off is lower LDL-C reduction potency (pravastatin 40 mg lowers LDL-C by approximately 34% vs. rosuvastatin 10 mg at 46%) [3].

Monitoring Protocol

A structured monitoring plan reduces the risk of serious adverse events. The following schedule reflects consensus transplant nephrology practice and KDIGO recommendations [11].

Baseline (before starting the combination): Obtain CK, comprehensive metabolic panel (including creatinine and eGFR), ALT, AST, fasting lipid panel, and sirolimus trough level. Patients with eGFR <30 mL/min/1.73 m² should not exceed rosuvastatin 5 mg daily per the drug's own labeling [4].

Week 4 to 6: Repeat CK, hepatic transaminases, and fasting lipid panel. Assess for myalgia symptoms using a standardized question: "Have you noticed any new muscle pain, tenderness, or weakness?"

Every 3 months for the first year: CK, lipid panel, renal function. After one year of stable therapy with no symptoms, extend monitoring to every 6 months.

At any time if symptoms develop: Obtain urgent CK. If CK exceeds 10 times the upper limit of normal or the patient reports dark urine, discontinue the statin immediately, check renal function, and consider hospitalization if rhabdomyolysis is suspected [7].

Dr. Robert Kalayjian, an infectious disease specialist at MetroHealth Medical Center, has advised: "The threshold for checking a CK should be very low in any patient on an mTOR inhibitor and a statin. A vague complaint of leg heaviness after exercise is enough to warrant labs" [13].

Special Populations

Transplant recipients on triple immunosuppression. If the regimen includes sirolimus plus mycophenolate plus corticosteroids, the steroid component can raise LDL-C by an additional 10 to 15%, increasing the need for statin therapy while the immunosuppressive burden amplifies myotoxicity risk. Extra caution with dosing applies [11].

Older adults (age 65 and above). Age-related decline in hepatic transporter expression reduces OATP1B1 activity by 20 to 40% [14]. This paradoxically may worsen the interaction: less hepatic uptake means more systemic statin exposure even without sirolimus co-administration. Start at rosuvastatin 5 mg and titrate conservatively.

Patients of East Asian descent. The rosuvastatin FDA label recommends a starting dose of 5 mg in Asian patients due to a roughly 2-fold increase in drug exposure observed in pharmacokinetic studies [4]. When sirolimus is added, the compounding of higher baseline exposure and transporter inhibition strengthens the case for 5 mg as a ceiling dose unless lipid targets are not met.

Patients with hypothyroidism. Untreated or undertreated hypothyroidism independently increases statin myotoxicity risk by 4 to 5-fold [7]. Check TSH before attributing muscle symptoms solely to the sirolimus-statin interaction.

What About Other Statins?

Not all statins carry equal interaction risk with sirolimus. The difference comes down to transporter dependence and CYP3A4 metabolism.

Simvastatin and lovastatin are CYP3A4 substrates. Sirolimus is a CYP3A4 substrate and weak inhibitor [1]. Co-administration can raise simvastatin and lovastatin levels through both CYP3A4 competition and OATP1B1 inhibition. Most transplant guidelines avoid simvastatin and lovastatin with mTOR inhibitors entirely [11].

Atorvastatin undergoes partial CYP3A4 metabolism (approximately 30%) but is also an OATP1B1 substrate [14]. It carries intermediate risk, and when prescribed with sirolimus, the recommended maximum is 20 mg daily.

Pitavastatin has minimal CYP metabolism and moderate OATP1B1 dependence. It may be a reasonable alternative in patients who need high LDL-C reduction without the CYP3A4 liability, though clinical data in the sirolimus population are sparse.

Rosuvastatin and pravastatin sit in the middle of the risk spectrum: no CYP3A4 metabolism, moderate OATP1B1 dependence. Rosuvastatin's superior potency makes it the more common choice when aggressive LDL-C lowering is needed.

Patient Counseling Points

Patients should receive clear instructions about three warning signs that require same-day medical contact: unexplained muscle pain that is new in onset and not related to exercise, dark or tea-colored urine, and unusual fatigue paired with muscle weakness. These are the classic triad of rhabdomyolysis symptoms [7].

Advise patients to avoid grapefruit juice in large quantities (more than 1 liter daily), as grapefruit inhibits OATP1A2 in the gut and could add another layer of transporter inhibition, though this effect is more relevant for fexofenadine than for rosuvastatin [14].

Hydration matters. Patients on mTOR inhibitors already face mild proteinuria risk [1]. Adding a statin that can, in rare cases, cause myoglobinuria places extra demand on the kidneys. Recommend at least 2 liters of fluid daily unless fluid restriction applies.

If the patient uses the combination for an off-label longevity protocol, confirm that they have a prescribing physician monitoring both the sirolimus trough levels and the statin safety labs. Self-managed sirolimus protocols without laboratory oversight carry unacceptable risk.

Rosuvastatin 5 mg daily, initiated with baseline labs and monitored at structured intervals, represents the safest starting configuration for patients who require both drugs.